Celera gains commercial strengh with BHL buy
This article was originally published in Clinica
Executive Summary
In agreeing to acquire Burlingame, California-based Berkeley HeartLab (BHL), molecular diagnostics specialist Celera is set to enter the rapidly-growing $7.8bn US market for personalised cardiovascular disease management.